GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algorae Pharmaceuticals Ltd (ASX:1AI) » Definitions » Quick Ratio

Algorae Pharmaceuticals (ASX:1AI) Quick Ratio : 26.84 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Algorae Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Algorae Pharmaceuticals's quick ratio for the quarter that ended in Dec. 2023 was 26.84.

Algorae Pharmaceuticals has a quick ratio of 26.84. It generally indicates good short-term financial strength.

The historical rank and industry rank for Algorae Pharmaceuticals's Quick Ratio or its related term are showing as below:

ASX:1AI' s Quick Ratio Range Over the Past 10 Years
Min: 3.33   Med: 9.88   Max: 26.84
Current: 26.84

During the past 13 years, Algorae Pharmaceuticals's highest Quick Ratio was 26.84. The lowest was 3.33. And the median was 9.88.

ASX:1AI's Quick Ratio is ranked better than
95% of 1541 companies
in the Biotechnology industry
Industry Median: 3.6 vs ASX:1AI: 26.84

Algorae Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Algorae Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algorae Pharmaceuticals Quick Ratio Chart

Algorae Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.33 9.88 6.14 17.86 9.35

Algorae Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.79 17.86 - 9.35 26.84

Competitive Comparison of Algorae Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Algorae Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algorae Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algorae Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Algorae Pharmaceuticals's Quick Ratio falls into.



Algorae Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Algorae Pharmaceuticals's Quick Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Quick Ratio (A: Jun. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(4.207-0)/0.45
=9.35

Algorae Pharmaceuticals's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(3.758-0)/0.14
=26.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algorae Pharmaceuticals  (ASX:1AI) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Algorae Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Algorae Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Algorae Pharmaceuticals (ASX:1AI) Business Description

Traded in Other Exchanges
Address
201 Sussex Street, Level 16, Tower 2, Darling Park, Sydney, NSW, AUS, 2000
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for undermet medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. Its lead products comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. It is conceptualised to be a potential treatment for dementia, including Alzheimer's disease; NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Algorae Pharmaceuticals (ASX:1AI) Headlines

No Headlines